Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Generics News
Amneal Gains US FDA Approval for Generic Version of Restasis for Dry Eye
Amneal Pharmaceuticals announced Dec. 1 that it had received US FDA approval for its cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. C...
Alembic Gains US FDA Approval for Generic of Bausch + Lomb’s Zylet
India’s Alembic Pharmaceuticals announced Dec. 11 that the US FDA had approved the abbreviated new drug application for its combination eye drop of loteprednol etabonate and tobramycin, referencing...
Mallinckrodt Spins Off Generics Business, Rebrands as Keenova
Drugmaker Mallinckrodt announced Nov. 10 that it had completed the planned spinoff of its Par Health generic pharmaceuticals and sterile injectables businesses and had rebranded as Keenova Therapeu...
October 2025 Ophthalmic News Briefs
Biotech Healthcare announced Sept. 23 that it had launched the Optiflex Xtense Comfort Plus extended-depth-of-focus (EDOF) intraocular lens at the ESCRS 2025 congress in Copenhagen, Denmark. Biotec...
Generic Drugmakers with US Sources Now Eligible for FDA Priority Review
The US FDA reported Oct. 3 that a new pilot program would speed the approval process for some generic drugmakers: They would be eligible for priority review if they conducted any required bioequiva...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.